Objective: Cardiac glucose metabolism is critical to normal and pathological function. The significance of the first committed metabolic step, glucose phosphorylation, has not been established. In this study a new transgenic model was developed in order to investigate the importance of this enzymatic step in cardiac glycolysis. Methods: Transgenic mice were produced that overexpress yeast hexokinase B under the control of a cardiac specific promoter. Yeast hexokinase B is a high affinity enzyme that is not inhibited by glucose-6-phosphate. Hexokinase enzyme activity was measured by a modified radiometric procedure. Cardiac glucose metabolism and contractility were measured in the Langendorff mode. Cardiac glycogen content and glucose-6-phosphate independent glycogen synthase activity were also determined. Results: In transgenic hearts hexokinase activity was significantly elevated and increased glucose metabolism, particularly in the presence of insulin and during cardiac reperfusion. However during ischemic perfusion the effect of the transgene on glycolysis was minimal. Under all conditions tested there was no effect of hexokinase on contractility. Glycogen content of transgenic hearts was elevated 2-fold and glucose-6-phosphate independent glycogen synthase was also increased. Conclusion: These results demonstrate that glucose phosphorylation is a key step in determining cardiac glucose metabolism under oxidative conditions.
Introduction
decline in glycolysis [4] that is associated with diabetic cardiomyopathy. In ischemic [5] hearts, dependence on Myocardial fuel metabolism is tightly regulated and glucose and glycolysis increases. In fact, stimulation of closely parallels the rate of cardiac work. Under most glycolysis with glucose and insulin has been used successcircumstances cardiac energy is derived primarily from fully to protect patient hearts from ischemic damage [6, 7] . fatty acids, while a small fraction is derived from glucose.
Unfortunately, our current understanding of the relationHowever, under pathological conditions the significance of ship between glycolysis and cardiac pathology is limited. glucose metabolism increases. Hypertrophy is known to
In part this is due to the fact that experimental manipulaincrease the reliance of the heart on glycolytic metabolism tions employed to modify glycolysis, such as fasting and [1] . It has also been found that natural [2] or experimental insulin treatment, affect many other systems. More specific [3] genetic mutations that impair glycolysis produce manipulations of cardiac carbohydrate metabolism are cardiac pathology. Similarly, diabetes produces a major needed to define its role in heart physiology and pathology. Glucose transport has been proposed to be rate limiting in skeletal and cardiac muscle glucose utilization. This conclusion was based largely on the finding that intracellu-becomes rate-limiting under conditions of hyperin-(NIH Publication No. 85-23, revised 1996). All animal sulinemia or hyperglycemia. Since intracellular glucose procedures were approved by the USDA certified institumust first be phosphorylated for further metabolism, tional animal care committee. hexokinase is implicated as a critical step for control of glucose utilization. To confirm this role for glucose 2.2. Analysis of transgene expression phosphorylation, transgenic animals have been bred that overexpress hexokinase II in skeletal and cardiac muscle
The activity and tissue specificity of the transgene were [12, 13] . Those studies observed relatively small effects of determined by measuring RNA on Northern blots and hexokinase overexpression on glucose homeostasis and enzyme activity in tissue homogenates. RNA for Northern cardiac glucose utilization [12, 13] . Heikkinen et al. [14] blots was prepared with RNazol as we have previously produced heterozygous hexokinase II knockout animals described [19, 20] from heart, liver, skeletal muscle, brain, with a 50% reduction in cardiac enzyme activity. These kidney and lung of transgenic and normal mice. A 1.3-kb animals also exhibited only a minor impact on metabolism.
NcoI / PstI fragment of the yeast hexokinase gene was 32 Hexokinase II is strongly inhibited by its product, glucoselabeled with P by random oligonucleotide priming and 6-phosphate (g6p). This self-regulation may limit the used as probe. This sequence had little detectable crossimpact of hexokinase II over-or under-expression on reactivity with any other mouse messenger RNA. overall glycolysis. The significance of this allosteric reguHexokinase enzyme activity was measured by a modilation was highlighted by the studies of Jimenez-Chillaron fication of the radiometric procedure of Bedoya et al. [21] . et al. [15] trations of glucose-6-phosphate (g6p). The incubation was To study the effects of glucose phosphorylation on then heated to 968C and 2 U of phosphoglucoisomerase cardiac glucose metabolism and to develop a model were added for an additional 60 min. After the addition of suitable for analyzing the impact of increased glucose 20 ml of 0.5 M HCl the formation of tritiated water was phosphorylation on cardiac ischemia and health, we assessed by diffusion overnight at 378C into 1 ml of water created a new transgenic mouse model that expresses yeast and scintillation counting. Counts were adjusted for the hexokinase B specifically in the heart. This hexokinase efficiency of diffusion and background samples that conisozyme is free of significant g6p inhibition. Transgenic tained no extract. animals exhibited no cardiac abnormalities. However, the elevated hexokinase activity resulted in enhanced gly-2.3. Cardiac perfusion colysis and increased glycogen storage in the heart, indicating that glucose phosphorylation is an important Langendorff perfusions were carried out by a modistep determining cardiac glucose utilization.
fication of a procedure previously reported by us [22] . Mice were anesthetized by i.p. injection of sodium pentobarbital 150 mg / kg administered with 100 IU of heparin.
Methods
The left side of the chest was opened. Through the incision the left lung was moved to the right side of the chest and 2.1. Development of transgenic mice the descending aorta isolated on the back wall. A suture was then placed around the aorta in preparation for The MyHEX transgene was produced by replacement of cannulation. A small incision was made in the descending the catalase coding sequences in the transgene MyCat [16] aorta to allow insertion of a cannula. The innominate with a 2700-bp fragment that contained all the coding artery, common carotid artery and subclavian artery were sequences of the yeast hexokinase B gene [17] , the SV40 then sutured and cut. The heart was removed from the early splice region and SV40 early polyadenylation site chest and transferred to the perfusion apparatus. The heart [18] . Prior to microinjection all plasmid sequences were was retrogradely perfused at 2 ml / min with Krebs-Henremoved by digestion with NotI. FVB mice were used to seleit buffer (KH) consisting of 120 mM NaCl, 20 mM produce transgenic lines containing the MyHEX transgene.
NaHCO , 4.6 mM KCl, 1.2 mM KH PO , 1.2 mM MgCl ,
Standard embryo microinjection procedures were used for 1.25 mM CaCl 5 mM glucose and 0.25 mCi/ml of 2 3 producing transgenic animals. The investigation conforms [5-H] glucose. Throughout the perfusion KH buffer was with the Guide for the Care and Use of Laboratory continuously equilibrated with 95% O / 5% CO which 2 2 Animals published by the US National Institutes of Health maintained a pH of 7.4 and temperature was maintained at 378C. The heart was paced throughout the procedure at 6 vol. of 50 mM HEPES buffer, pH 7.4, containing 50 mM Hz (6 V, 3 ms). For studies on the effect of ischemia, sodium pyrophosphate, 10 mM sodium fluoride, 10 mM baseline glycolysis was determined during the first 60 min.
EDTA, and 5 ml / ml of protease inhibitor cocktail (Sigma, Next, the heart was subject to a 60-min period of low-flow P 8340). The homogenate was centrifuged at 10,0003g, ischemia. This was achieved by switching a three-way 08C for 15 min. A 30-ml aliquot of supernatant was added valve to another perfusion line running from a buffer to 60 ml of an assay buffer containing 50 mM Tris-HCl, reservoir bubbled with 95% N and 5% CO to ensure pH 7.0, 20 mM EDTA, 25 mM potassium fluoride, bovine 2 2 hypoxia and a buffer pH of 7.4. The ischemic flow rate liver glycogen (5 mg / ml) and 8 mM uridine diphospho-D- 14 was 0.15 ml / min. For the last hour the heart was again [U-C]glucose (0.05 mCi). Separate assays were perperfused with 95% O and 5% CO equilibrated KH buffer formed at pH 8.5 with 2.0 mM glucose-6-phosphate as 2 2 at 2.0 ml / min. For studies on the effect of insulin, baseline activator of the b form. The mixture was incubated at 308C glycolysis was determined for the first 30 min followed by for 20 min, and then boiled in a water bath for 10 min to 50 min in the presence of 200 mU / ml insulin. Perfusion terminate the enzyme reaction. Then 75 ml of the reaction 2 pressure was monitored on a Gould / Statham p23Db mixture was spotted onto a 232-cm filter paper, which physiological pressure transducer. Contractile force was was washed twice in 66% ethanol and once with acetone measured by means of a Grass FT03 force transducer prior to liquid scintillation counting. hooked to the apex of the heart. Transducers were connected to a ETH 400 bridge amplifier which fed into a 2.7. Assay of cardiac glucose-6-phosphate (g6p) Powerlab / 400 amplifier. Data was analyzed using AD Instruments Chart for Windows version 3.3.5.
Hearts were quickly blotted and frozen in liquid nitrogen. The frozen tissue was weighed and homogenized in 9 2.4. Measurements of glycolysis and lactate production vol. of 1.0 M perchloric acid. The extract was centrifuged at 12,0003g for 5 min and the supernatant neutralized to 3 Tritiated water produced from [5-H] glucose during the pH 7.4. The concentration of g6p was measured against perfusion was determined by diffusion. A 400-ml sample g6p standards by a fluorometric procedure [23] employing of cardiac effluent and 25 ml of 0.6 N HCl were added to NADP and glucose 6-phosphate dehydrogenase. 1.5-ml tubes that were placed inside 20-ml scintillation vials containing 2 ml water. Vials were incubated for 72 h 2.8. Statistical analysis at 378C. The inside tube was removed and scintillant added for counting. Effluent from each time point was assayed in Statistical analysis of hexokinase activity was carried triplicate. For each experiment, background counts were out by one-way ANOVA followed by Bonferroni post-hoc determined by performing the same equilibration on test. For comparisons of contractility, glycolysis and perfusion media that had not passed through the heart. lactate production, values were subject to two-way Diffusion efficiency was also measured in each experiment ANOVA for repeated measures and post-hoc analysis by using tritiated water. Lactate concentration was measured Student-Newman-Keuls test. Pair wise comparisons for in 6-fold dilution of oxygenated or 24-fold dilution of values obtained under the same experimental conditions ischemic effluent using Sigma kit 826-B.
for glycogen content, glycogen synthase activity and perfused heart function, were made using Student's t-test.
Glycogen assay
The accepted level of significance was 0.05.
The heart was quickly removed, blotted dry, and frozen with liquid nitrogen. The frozen tissue was weighed, 3. Results homogenized in 9 vol. of 0.03 N HCl at 08C and then heated in a boiling water bath for 5 min. Then 10 ml of 3.1. Generation of transgenic mice expressing yeast homogenate glycogen was hydrolyzed to glucose by the hexokinase B in the heart addition of 50 ng amyloglucosidase (Boehringer-Mannheim) in 100 ml of 0.1 M acetate buffer, pH 4.7. Glucose A transgene designated MyHEX was constructed with was then measured by fluorometric assay using hexokinase the yeast hexokinase B gene. To achieve cardiac expresand glucose-6-phosphate dehydrogenase [23] . For each sion, the transgene was regulated by a 5000-bp portion of sample assays were performed with and without amylogthe cardiac specific alpha myosin heavy chain (MHC) gene lucosidase to distinguish glucose derived from glycogen [24] , consisting of the promoter and the first two introns. from preexisting cardiac glucose.
Four transgenic lines of mice were produced with the MyHEX gene. Line 188 demonstrated the clearest increase 2.6. Assay of glycogen synthase in cardiac enzyme activity, which was enhanced 2-fold when animals were bred to homozygosity (data not The heart was blotted dry and homogenized on ice in 9
shown). In all subsequent assays homozygous line 188 transgenic hearts. The fact that the hexokinase activity in non-transgenic hearts was suppressed to a much greater extent by g6p than activity in transgenic hearts was consistent with the differential sensitivities of yeast hexokinase B and mammalian hexokinase to feed back inhibition by g6p. It is noteworthy that the increase in hexokinase activity in transgenic hearts increased gradually and reproducibly from 8 to 12.5 to 26 pmol glucose / mg tissue per h at 0, 0.46 and 3 mM g6p, respectively. Expression of yeast hexokinase mRNA was used to assess the tissue specificity of the transgene. The Northern blot shown in Fig. 2 demonstrated that the transgene was active primarily in the heart. colysis was assessed in Langendorff perfused hearts. Glycolysis was evaluated by determining the release of mice were used. These mice were healthy with no indicatritiated water from 5-tritiated glucose, which measures tions of increased mortality or reduced fertility over a glycolytic steps through the triose phosphate isomerase period of more than 1 year. No morphological abnorreaction. As shown in Fig. 3A , glycolysis was greater in malities were noted and heart to body weight ratios did not transgenic hearts, and this difference was significant at suggest cardiac hypertrophy (ratios of heart to body weight most time points before adding insulin and at all time in mg / g of 4.560.1 and 4.360.1 for control and MyHEX points after the addition of insulin (P#0.05). Before the mice, respectively, n511 per group, P.0.1).
addition of insulin the average glycolytic rate was greater by |250 pmol glucose / min per mg heart. Adding insulin 3.2. Enzymatic and Northern analysis of transgene stimulated glycolysis in all hearts and increased the expression average difference between transgenic and control hearts by an additional 100 pmol glucose / min per mg. Cardiac To estimate the increase in hexokinase activity in vivo contractility and perfusion pressure were measured to we performed enzyme assays at three different g6p condetermine whether these parameters influenced glycolysis. centrations. As shown in Fig. 1 , the hexokinase activity Throughout the assay, contractility (Fig. 3B ) and perfusion from transgenic hearts was increased 12, 67 and 680% pressure (Fig. 3C ) were stable and essentially identical in over the non-transgenic controls when measured at 0, 0.46 control and transgenic hearts. Cardiac g6p, measured at the and 3 mM g6p, respectively. Since 0.46 mM g6p approxiend of the insulin exposure in these hearts, was the same mates intracellular cardiac g6p level [25] , these data for FVB and MyHEX, 37769.5 and 365628 mM, respecsuggest that in vivo activity was increased by |67% in tively. An additional four hearts of each type were assayed acidifying the heart. We examined the effect of the hexokinase transgene by assessing glycolysis, lactate production and contractility during ischemia and reperfusion (Fig. 4) . The transgene appeared to increase glycolysis before and after ischemia, however unlike the results obtained for Fig. 3 , this trend did not reach significance when assessed by two-way ANOVA for repeated measures. The difference in lactate production of transgenic and control hearts did reach significance. Post-hoc analysis revealed a significant increase in lactate production during the reperfusion phase. The failure to obtain a significant effect of the hexokinase transgene on glycolysis may have been due to the very similar rates of glycolysis in the two for g6p after 20 min of perfusion without insulin. These hearts had g6p levels of 163614 and 183626 mM for FVB and MyHEX hearts, respectively. 
Effects of yeast hexokinase B on glycogen and glycogen synthase
We measured cardiac glycogen content as an indicator of the transgene effect on in vivo cardiac metabolism. Yeast hexokinase produced a 2-fold increase in cardiac glycogen content. This was apparent in both free fed and fasted mice (Fig. 5) . In mice, unlike rats, fasting does not increase cardiac glycogen content [26, 27] . Important factors determining cardiac glycogen include glycogen synthase activity and g6p concentration. As shown in Fig. 6 , g6p independent glycogen synthase activity was increased in 
Discussion
groups during the ischemic period. It is also worth noting that at most time points during the basal and reperfusion
To study the role of glucose phosphorylation in the phase of perfusion, glycolysis and lactate production were regulation of cardiac fuel metabolism and pathology we greater in transgenic hearts than in control hearts by produced transgenic mice that express yeast hexokinase B Student's t-test (P,0.05). In MyHEX hearts average rates specifically in cardiac myocytes. The transgene increased of glycolysis and lactate production were greater during hexokinase activity and produced no detectable cardiac the reperfusion phase than during the basal phase (P, pathology. In Langendorff perfused hearts overexpression 0.05). This is different from what was observed in FVB of hexokinase increased glycolysis under oxidative conhearts where glycolysis and lactate production were almost ditions in the presence or absence of insulin, but glycolysis the same before and after ischemia. During ischemia, was not significantly altered under ischemic cardiac conneither glycolysis nor lactate production were clearly ditions. Accordingly, we found no protective effect of the altered by the transgene. As shown in Fig. 4C , contractility transgene on ischemia-induced deficits in contractility. In was markedly affected by ischemia and reperfusion (P, vivo glycogen content of transgenic hearts was elevated 0.05), but the hexokinase transgene had no impact on 2-fold, which was in part due to increased g6p independent contractility during any phase of perfusion.
glycogen synthase activity. These results provide direct evidence in support of the contention that glucose phosphorylation under certain conditions can regulate the rate of cardiac glucose metabolism. In MyHEX mice cardiac hexokinase activity was increased by 680% in the presence of 3 mM g6p, 67% at 0.46 mM g6p and by 12% in the absence of g6p. Based on our measured values of g6p the percentage increase in our perfused hearts was close to 67% in the presence of insulin. This g6p dependent variation in percentage increase was expected since endogenous hexokinases are inhibited by g6p while yeast hexokinase is not. What was not expected was that the absolute difference between transgenic and control hexokinase activity would decrease from 26 down to 8 pmol glucose / mg tissue per h when the g6p level was reduced from 3 to 0 mM (Fig. 1) . Additional experiments verified this finding (data not shown). These results imply either that the transgene was less active at g6p sensitive, endogenous hexokinase is consistent with did not increase glycolysis during ischemia. Thus it was the values we obtained in these assays. Autoregulation of not surprising that ischemia was equally damaging to hexokinase expression by hexokinase activity has not been contractility in transgenic and control hearts. Lactate is the examined in mammals but has been demonstrated in yeast primary end product of glycolysis under hypoxic con- [29] . More specific examinations of altered endogenous ditions. By acidifying the myocyte, lactate contributes to hexokinase RNA and protein expression in our transgenic ischemic damage. Therefore we measured lactate prohearts are clearly needed to confirm this hypothesis. If duction during ischemia and reperfusion assays. While indeed endogenous hexokinase was reduced by transgenic lactate production was similar in transgenic and control yeast hexokinase expression then the functional impact of hearts during ischemia, during reperfusion lactate prothe transgene would be less.
duction was significantly higher in MyHEX hearts and Values of g6p in transgenic and control hearts were not failed to return to basal levels. In transgenic hearts lactate significantly different. This implies that the increased g6p production was 44% higher during reperfusion than during generated by yeast hexokinase must have been rapidly the basal period. This suggests that there may have been incorporated into glycogen or utilized in glycolysis. This is less recovery of oxidative metabolism in transgenic hearts. consistent with the increase in glycogen synthase, Alternatively, it may also have been due to the fact that glycogen content and glycolytic rate that we observed. glycolysis in transgenic hearts was 31% higher during Prior studies in skeletal muscle with hexokinase IV [15] reperfusion than during the basal period. A possible have shown that overexpression increased g6p, however mechanism for increased glycolysis during reperfusion of similar studies with hexokinase II did not result in inMyHEX hearts is that ischemia stimulates recruitment of creased g6p [30] .
glucose transporters and increases glucose uptake [35] .
Glycolysis in Langendorff perfused MyHEX hearts was
The increased glucose uptake may increase the relative increased by 250 pmol glucose / min per mg heart, which effect of the yeast hexokinase transgene, as we also saw was between 30 and 50% of the total glycolysis of control during perfusion with insulin. hearts. This demonstrated that elevated hexokinase activity Alterations in glycolysis are associated with several enhanced glucose metabolism, at least in the absence of cardiac pathologies. In cardiac hypertrophy and congestive insulin. The effect of insulin was assessed by adding it to heart failure [1] glycolysis increases in the heart. Conthe perfusion buffer. Insulin widened the separation beversely, in diabetes there is a reduction in cardiac glytween control and transgenic glycolysis by an additional colysis, which may predispose the heart to diabetic car-100 pmol glucose / min per mg heart. This was probably diomyopathy. Because each of these pathologies impacts due to increased glucose uptake, which put a greater multiple metabolic and second messenger systems in the substrate load on hexokinase. The effect of the transgene heart it has been impossible to tease out the importance of on glycolysis could not have been due to altered contracglycolysis. It is even unclear whether these changes are tility since this parameter was indistinguishable in control beneficial or detrimental to the heart. This transgenic and transgenic hearts.
mouse provides a direct approach to analyze the role of During the ischemic phase of perfusion, the difference glycolysis in these diseases. We saw no damage to the between transgenic and control metabolism was minimal.
heart even in transgenic mice over a year in age. By The reduced impact of hexokinase during ischemia sugcrossing this and other transgenic models that increase gests a shift in regulation of glycolysis away from hexglycolysis with available models of cardiac failure we hope okinase. This is consistent with reports that glyceraldehyde to be able to discern if increased glycolysis can be 3-phosphate dehydrogenase [31] and 2-phosphofructoprotective to the heart. kinase [32] are inhibited during severe cardiac ischemia. Since ischemia stimulates glycogen breakdown [33], the diminished difference in glycolysis may also be due to the
